Suche klinische Studie
Weitere Suchoptionen
57 Ergebnis(se)
Rekrutierende Studie = 
; Fortlaufende Studie = 
; Förderung durch ein IRDiRC-Mitglied = 
; ERN-Mitglied = 
Nationale klinische Studie(n)
DEUTSCHLAND
Baden-Württemberg
HEIDELBERG
INFORM2 NivEnt: Explorative multinationale Phase I/II-Kombinationsstudie von Nivolumab und Entinostat bei Kindern und Jugendlichen mit refraktären Hochrisikomalignomen
Deutsches Krebsforschungszentrum
Klinische Kooperationseinheit Pädiatrische Onkologie
DEUTSCHLAND
Baden-Württemberg
STUTTGART
CWS-2007-HR: Eine randomisierte Phase-III-Studie für lokalisiertes Hochrisiko-Rhabdomyosarkom und lokalisiertes Rhabdomyosarkom-artiges Weichteilsarkom bei Kindern, Jugendlichen und jungen Erwachsenen
Klinikum Stuttgart - Standort Olgahospital
Pädiatrie 5 - Onkologie, Hämatologie und Immunologie
DEUTSCHLAND
Bayern
REGENSBURG
INFORM2 NivEnt: Explorative multinationale Phase I/II-Kombinationsstudie von Nivolumab und Entinostat bei Kindern und Jugendlichen mit refraktären Hochrisikomalignomen
Universitätsklinikum Regensburg
Abteilung für Pädiatrische Hämatologie, Onkologie und Stammzelltransplantation
DEUTSCHLAND
Berlin
BERLIN
PazoQol: Lebensqualität bei Patienten mit nicht-adipozytärem Weichgewebssarkom unter palliativer Chemotherapie oder Pazopanib -eine randomisierte, kontrollierte Studie
Helios Klinikum Emil von Behring
Klinik für Onkologie
DEUTSCHLAND
Hessen
FRANKFURT AM MAIN
OlaReDo: Wirksamkeit von Olaratumab und Wiederauftreten mit Doxorubicin bei Anthrazyklin vorbehandelten, fortgeschrittenen Weichteilsarkompatienten. Eine explorative Phase-II-Studie
Krankenhaus Nordwest GmbH
Institut für Klinisch-Onkologische Forschung
DEUTSCHLAND
Nordrhein-Westfalen
ESSEN
INFORM2 NivEnt: Explorative multinationale Phase I/II-Kombinationsstudie von Nivolumab und Entinostat bei Kindern und Jugendlichen mit refraktären Hochrisikomalignomen
Universitätsklinikum Essen
Klinik für Kinderheilkunde III - Abteilung für pädiatrische Hämatologie und Onkologie
IRLAND
County Dublin
DUBLIN
A Protocol For Nonmetastatic Rhabdomyosarcoma [RMS-2005] (Phase III) - IE
Children's Health Ireland @ Crumlin
National Oncology/ Bone Marrow Transplant Centre and Haematology Department
OSTERREICH
WIEN
WIEN
Phase I/II Open Label, Dose Escalation Trial to Determine the MTD, Safety, PK and Efficacy of Afatinib Monotherapy in Children Aged 1 Year to <18 Years With Recurrent/Refractory Neuroectodermal Tumours, Rhabdomyosarcoma and/or Other Solid Tumours With Known ErbB Pathway Deregulation Regardless of Tumour Histology - AT
St. Anna Kinderspital
Zentrum für Kinder- und Jugendheilkunde
OSTERREICH
WIEN
WIEN
A Randomised Phase-III Trial of the Cooperative Weichteilsarkom Study Group (CWS) for Localised High-risk Rhabdomyosarcoma and Localised Rhabdomyosarcoma-like Soft Tissue Sarcoma in Children, Adolescents, and Young Adults - AT
St. Anna Kinderspital
Zentrum für Kinder- und Jugendheilkunde
POLEN
Lublin
LUBLIN
Multicenter, Open-label Study to Assess the Pharmacokinetics (PK), Pharmacodynamics (PD), Efficacy, Safety, Tolerability, and Immunogenicity of a Single, Subcutaneous Dose of 100µg/kg XM22 in 21 Children With Ewing Family of Tumors or Rhabdomyosarcoma - PL
Uniwersytecki Szpital Dzieciecy w Lublinie
Klinika Hematologii I Onkologii Dzieciecej
SCHWEIZ
Suisse Romande
ADDRESS: NOT PROVIDED - CH
ANNOUNCE 2: A Phase 1b (Open-Label) / Phase 2 (Randomized,Double-Blinded) Study Evaluating Gemcitabine andDocetaxel With or Without Olaratumab in the Treatment ofAdvanced Soft Tissue Sarcoma -GB
Institution: Information not provided - CH
SCHWEIZ
Suisse Romande
ADDRESS: NOT PROVIDED - CH
PazoQol: Quality of life in patients with non-adipocyte soft tissue sarcoma underpalliative chemotherapy or pazopanib - a randomized, controlled trial - CH
Institution: Information not provided - CH
SPANIEN
Andalucía
SEVILLA
ANNOUNCE 2: A Phase 1b (Open-Label) / Phase 2 (Randomized, Double-Blinded) Study Evaluating Gemcitabine and Docetaxel With or Without Olaratumab in the Treatment of Advanced Soft Tissue Sarcoma - ES
Hospital Universitario Virgen del Rocío
Unidad de Oncología Médica, Oncología Radioterápica y Radiofísica
SPANIEN
Cataluńa
BARCELONA
ANNOUNCE 2: A Phase 1b (Open-Label) / Phase 2 (Randomized, Double-Blinded) Study Evaluating Gemcitabine and Docetaxel With or Without Olaratumab in the Treatment of Advanced Soft Tissue Sarcoma - ES
Hospital Universitari Vall d'Hebron
Servicio de Oncología Médica
SPANIEN
Madrid
MADRID
ANNOUNCE 2: A Phase 1b (Open-Label) / Phase 2 (Randomized, Double-Blinded) Study Evaluating Gemcitabine and Docetaxel With or Without Olaratumab in the Treatment of Advanced Soft Tissue Sarcoma - ES
Hospital Universitario 12 de Octubre
Servicio de Oncología Médica
SPANIEN
Madrid
MADRID
ANNOUNCE 2: A Phase 1b (Open-Label) / Phase 2 (Randomized, Double-Blinded) Study Evaluating Gemcitabine and Docetaxel With or Without Olaratumab in the Treatment of Advanced Soft Tissue Sarcoma - ES
Hospital Universitario La Paz
Servicio de Oncología Médica
VEREINIGTES KONIGREICH
South Glamorgan
CARDIFF
EpSSG-RMS-2005: A Protocol For Nonmetastatic Rhabdomyosarcoma (Phase IV) - UK
Children's Hospital for Wales
Department of Paediatric Oncology
VEREINIGTES KONIGREICH
South Yorkshire
SHEFFIELD
Axi-STS: A clinicopathological phase II study of axitinib in patients with advanced angiosarcoma and other soft tissue sarcomas
Weston Park Hospital
Cancer Clinical Trials Centre
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
ADDRESS: NOT PROVIDED - BE
CREATE (EORTC-90101): Cross-tumoral Phase 2 clinical trial exploring Crizotinib (PF-02341066) in patients with advanced tumor induced by causal alterations of ALK and/or MET - BE
Institution: Information not provided - BE
DEUTSCHLAND
Baden-Württemberg
HEIDELBERG
Retro-Ion: Neoadjuvante Bestrahlung von retroperitonealem Weichteilsarkom mit Ionen Retro-Ionen Prospektive Randomisierte Phase-II-Studie
Neurologische Universitätsklinik Heidelberg
Klinik für Radioonkologie und Strahlentherapie
DEUTSCHLAND
Nordrhein-Westfalen
ESSEN
CREATE: Tumorübergreifende klinische Phase-2-Studie zur Erforschung von Crizotinib (PF-02341066) bei Patienten mit fortgeschrittenem Tumor ausgelöst durch kausale Veränderungen der ALK und/oder MET
Westdeutsches Tumorzentrum Essen (WTZ)
Klinik für Innere Medizin (Tumorforschung)
DEUTSCHLAND
Nordrhein-Westfalen
KÖLN
EORTC 62072 (PALETTE) - Eine randomisierte, doppelblinde zu Pazopanib im Vergleich zu einem Placebo bei Patienten mit Weichteilsarkomen, deren Erkrankung während oder nach einer vorangegangenen Therapie wieder an Größe zugenommen hat
Universitätsklinikum Köln
Klinik I für Innere Medizin - AG Prof. Wendtner
DEUTSCHLAND
Nordrhein-Westfalen
MÜNSTER
FIBROSARC : Eine Phase-III-Studie zum Vergleich der Wirksamkeit von Doxorubicin in Kombination mit dem tumorspezifischen humanen Antikörper-Zytokin-Fusionsprotein L19TNF und Doxorubicin allein als Erstlinientherapie bei Patienten mit fortgeschrittenem oder metastasiertem Weichteilsarkom - DE
Universitätsklinikum Münster
Medizinische Klinik und Poliklinik A
FRANKREICH
AUVERGNE-RHONE-ALPES
ADDRESS: NOT PROVIDED - FR
An Open-label, Multi-center, Randomized Study of the Safety and Effect on Event-free Survival of Bevacizumab in Combination With Standard Chemotherapy in Childhood and Adolescent Patients With Metastatic Rhabdomyosarcoma and Non-rhabdomyosarcoma Soft Tissue Sarcoma (Phase II) - FR
Institution: Information not provided - FR
FRANKREICH
AUVERGNE-RHONE-ALPES
ADDRESS: NOT PROVIDED - FR
A randomized Phase 3, multicenter, Open-Label Study comparing TH-302 in Combination with Doxorubicin vs. Doxorubicin alone in subjects with locally advanced unresectable or metastatic soft tissue sarcoma - FR
Institution: Information not provided - FR
FRANKREICH
AUVERGNE-RHONE-ALPES
ADDRESS: NOT PROVIDED - FR
ANITA: A Phase II Multicenter Study Comparing the Efficacy of the Oral Angiogenesis Inhibitor Nintedanib With the Intravenous Cytotoxic Compound Ifosfamide for Treatment of Patients With Advanced Metastatic Soft Tissue Sarcoma After Failure of Systemic Non-oxazaphosporine-based First Line Chemotherapy for Inoperable Disease - FR
Institution: Information not provided - FR
FRANKREICH
AUVERGNE-RHONE-ALPES
LYON
Multicenter phase I/II study of continuous dosing of Sunitinib in non-GIST sarcomas with concomitant radiation therapy.
CLCC Léon Bérard
Radiothérapie
FRANKREICH
NOUVELLE AQUITAINE
BORDEAUX
RADIOSARP : A Phase Ib Study of Olaparib With Concomitant Radiotherapy in Locally Advanced/Unresectable Soft-tissue Sarcoma
CLCC Institut Bergonié
Département d'oncologie médicale - Sarcomes
FRANKREICH
NOUVELLE AQUITAINE
BORDEAUX
TRAMUNE : Trabectedin Combined With Durvalumab (MEDI4736) in Patients With Advanced Pretreated Soft-tissue Sarcomas and Ovarian Carcinomas : A Phase Ib Study
CLCC Institut Bergonié
Département d'oncologie médicale - Sarcomes
FRANKREICH
NOUVELLE AQUITAINE
BORDEAUX
TARMIC : Targeting Microenvironment and Cellular Immunity in Sarcomas Weekly trabectedin combined with Metronomic Cyclophosphamide in Patients with Advanced Pretreated Soft-tissue Sarcomas. A Phase I/II study from the French Sarcoma Group
CLCC Institut Bergonié
Département d'oncologie médicale - Sarcomes
OSTERREICH
WIEN
ADDRESS: NOT PROVIDED - AT
An Open-Label, Multicohort, Phase II Study of Atezolizumab in Advanced Solid Tumors (Phase 2) - AT
Institution: Information not provided - AT
OSTERREICH
WIEN
WIEN
A Multicenter Phase 1, Open-Label Study of DCC-2618 to Assess Safety, Tolerability, and Pharmacokinetics in Patients With Advanced Malignancies - AT
Allgemeines Krankenhaus der Stadt Wien
Klinische Abteilung für Hämatologie und Hämostaseologie
OSTERREICH
WIEN
WIEN
ANNOUNCE: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Doxorubicin Plus Olaratumab Versus Doxorubicin Plus Placebo in Patients With Advanced or Metastatic Soft Tissue Sarcoma - AT
Allgemeines Krankenhaus der Stadt Wien
Klinische Abteilung für Onkologie
OSTERREICH
WIEN
WIEN
INFORM2 NivEnt: Exploratory Multinational Phase I/II Combination Study of Nivolumab and Entinostat in Children and Adolescents With Refractory High-risk Malignancies - AT
St. Anna Kinderspital
Zentrum für Kinder- und Jugendheilkunde
SCHWEIZ
Suisse Alémanique
ST. GALLEN
NAPAGE: NAb-PAclitaxel and GEmcitabine in Advanced Soft Tissue Sarcoma. A Multicenter Open-label Single Arm Phase Ib/IIa Trial
Kantonsspital St. Gallen
Klinik für Medizinische Onkologie und Hämatologie; Klinik für Neurologie
SCHWEIZ
Suisse Romande
LAUSANNE
NAPAGE: NAb-PAclitaxel and GEmcitabine in Advanced Soft Tissue Sarcoma. A Multicenter Open-label Single Arm Phase Ib/IIa Trial
Centre Hospitalier Universitaire Vaudois CHUV
Département d'oncologie
SPANIEN
Andalucía
SEVILLA
GEIS-51: Phase II multicenter trial of palbociclib in second line of advanced sarcomas with CDK4 overexpression - ES
Hospital Universitario Virgen del Rocío
MUsculoSkeletal Tumor Board of Excellence Sevilla (MUSTBE SEVILLA)
SPANIEN
Cataluńa
BADALONA
GEIS-51: Phase II multicenter trial of palbociclib in second line of advanced sarcomas with CDK4 overexpression - ES
ICO Badalona - Hospital Germans Trias i Pujol
Servicio de Oncología Médica
SPANIEN
Comunidad Valenciana
VALENCIA
ANNOUNCE: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Doxorubicin plus Olaratumab versus Doxorubicin plus Placebo in Patients with Advanced or Metastatic Soft Tissue Sarcoma - ES
Hospital Universitario y Politécnico La Fe
Servicio de Oncología Médica
SPANIEN
Madrid
MADRID
Randomized, double-blind, 3-arm trial to evaluate the impact of blood loss following administration of three tranexamic acid regimens in patients undergoing bone or soft tissue sarcomas (Phase III) - ES
IdiPAZ - Instituto de Investigación Sanitaria del Hospital Universitario La Paz
Unidad Central de Investigación Clínica y Ensayos Clínicos del Hospital La Paz
UNGARN
Észak-Alföld
DEBRECEN
A Phase 1b (Open-Label) / Phase 2 (Randomized, Double-Blinded) Study Evaluating Gemcitabine and Docetaxel With or Without Olaratumab in the Treatment of Advanced Soft Tissue Sarcoma
Debreceni Egyetem Klinikai Központ Onkológiai Intézet
Institute of Oncology
VEREINIGTES KONIGREICH
Greater London
LONDON
A Phase 1/2, First in Human, Single-arm, Open-label Study of Once a Day, Orally Administered BMN 673 in Patients with Advanced or Recurrent Solid Tumors - UK
Royal Marsden Hospital
Drug Development Unit
VEREINIGTES KONIGREICH
Greater London
LONDON
CREATE (EORTC 90101): Cross-tumoral Phase 2 clinical trial exploring Crizotinib (PF-02341066) in patients with advanced tumours induced by causal alterations of either ALK or MET - UK
UCLH NHS Foundation Trust - University College Hospital
The London Sarcoma Service
VEREINIGTES KONIGREICH
Greater Manchester
ADDRESS: NOT PROVIDED - UK
NGR016: Randomized phase II study evaluating two doses of NGR-hTNF administered either as single agent or in combination with doxorubicin in patients with advanced soft-tissue sarcoma (STS) - UK
Institution: Information not provided - UK
VEREINIGTES KONIGREICH
Greater Manchester
ADDRESS: NOT PROVIDED - UK
A Randomized, Multicenter, Phase III Trial of Trabectedin (Yondelis®) versus Doxorubicin-based Chemotherapy as First-Line Therapy in Patients with Translocation-Related Sarcomas (TRS) - UK
Institution: Information not provided - UK
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
STEP: Sorafenib Long Term Extension Program - BE
Cliniques universitaires Saint-Luc - UCLouvain
Pneumologie_Oncologie thoracique
FRANKREICH
ILE-DE-FRANCE
GARCHES
Long-Term Effect of LIAM (Lung Insufflation Assist Maneuver) on Respiratory Performance in Non-invasive Ventilated Patients Suffering From Neuromuscular Disease
CHU Paris IdF Ouest - Hôpital Raymond Poincaré
Centre d'Investigation Clinique et Technologique 805 - CIC-IT de Garches
FRANKREICH
ILE-DE-FRANCE
GARCHES
Establishment of a Non-invasive and Indirect Measure of Volitional Pimax (PI MAX STIM)
CHU Paris IdF Ouest - Hôpital Raymond Poincaré
Service de Physiologie-Explorations Fonctionnelles
Multinationale klinische Studie(n)
DEUTSCHLAND
Baden-Württemberg
ULM
SCHWEIZ
Suisse Alémanique
BASEL
A Phase II Trial of R1507, a Recombinant Human Monoclonal Antibody to the Insulin-Like Growth Factor-1 Receptor for the Treatment of Patients With Recurrent or Refractory Ewing's Sarcoma, Osteosarcoma, Synovial Sarcoma, Rhabdomyosarcoma and Other Sarcomas (coordination)
Hoffmann-La Roche
Hoffmann - La Roche Ltd.
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
ANNOUNCE 2: A Phase 1b (Open-Label) / Phase 2 (Randomized,Double-Blinded) Study Evaluating Gemcitabine andDocetaxel With or Without Olaratumab in the Treatment ofAdvanced Soft Tissue Sarcoma
Institution: Information not provided - US
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
A Phase 1b Trial to Assess the Modulation of Biological Markers in Patients With Potentially Resectable Soft Tissue Sarcoma Treated With Olaratumab Monotherapy Followed by Olaratumab Plus Doxorubicin Combination Therapy
Institution: Information not provided - US
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
ADDRESS: NOT PROVIDED - BE
CREATE: Cross-tumoral Phase 2 clinical trial exploring Crizotinib (PF-02341066) in patients with advanced tumor induced by causal alterations of ALK and/or MET
Institution: Information not provided - BE
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
ADDRESS: NOT PROVIDED - BE
ANITA: A Phase II Multicenter Study Comparing the Efficacy of the Oral Angiogenesis Inhibitor Nintedanib With the Intravenous Cytotoxic Compound Ifosfamide for Treatment of Patients With Advanced Metastatic Soft Tissue Sarcoma After Failure of Systemic Non-oxazaphosporine-based First Line Chemotherapy for Inoperable Disease
Institution: Information not provided - BE
VEREINIGTE STAATEN
Kansas
LAWRENCE
A Multicenter Phase 1, Open-Label Study of DCC-2618 to Assess Safety, Tolerability, and Pharmacokinetics in Patients With Advanced Malignancies
Deciphera Pharmaceuticals, LLC.
VEREINIGTE STAATEN
New York
NEW YORK
A randomized Phase 3, multicenter, Open-Label Study comparing TH-302 in Combination with Doxorubicin vs. Doxorubicin alone in subjects with locally advanced unresectable or metastatic soft tissue sarcoma - coordination
Memorial Sloan-Kettering Cancer Center
Department of Medicine Melanoma and Sarcoma Service
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US